Some men may experience vision changes after taking Fildena Chewable 100 mg due to the pharmacological effects of sildenafil citrate, the active ingredient in Fildena Chewable and other medications like Viagra.
Sildenafil citrate, a phosphodiesterase type 5 (PDE5) inhibitor, primarily works by increasing blood flow to the penis, which helps men achieve and maintain an erection. However, sildenafil citrate can also affect the blood vessels in other parts of the body, including the eyes.
Vision changes associated with sildenafil citrate use may include:
Changes in Color Perception: Some men may perceive a blue-green tint to their vision, or they may have difficulty distinguishing between blue and green colors. This effect is typically mild and temporary.
Blurry Vision: Some individuals may experience mild blurriness or changes in visual acuity after taking sildenafil citrate.
Increased Sensitivity to Light: Sildenafil citrate may cause increased sensitivity to light or difficulty adjusting to changes in lighting conditions.
These vision changes are generally mild and temporary, resolving on their own within a few hours of taking the medication. However, in rare cases, more severe vision changes, including sudden vision loss, have been reported with the use of sildenafil citrate.
If you experience sudden or severe vision changes after taking Fildena Chewable 100 mg or any medication containing sildenafil citrate, it’s essential to seek immediate medical attention. Sudden vision changes may be a sign of a serious underlying medical condition that requires prompt evaluation and treatment.
Overall, while vision changes are a potential side effect of sildenafil citrate, they are relatively uncommon and usually mild. However, if you have concerns about vision changes or any other side effects associated with Fildena Chewable 100 mg, it’s important to discuss them with your healthcare provider. They can provide guidance and recommendations based on your individual health status and medication regimen.
Call: 876-927-9941–3 .
